Cancer patients denied life-extending drug

People with advanced liver cancer will be denied a new drug on the NHS under draft guidance published today.



The National Institute for Health and Clinical Excellence (Nice) said the price being charged by pharmaceutical firm Bayer for the medicine was "simply too high". Treatment with the drug costs £36,000 a year per patient.

But cancer charities said it was a "scandal" that patients are being refused the only drug that has been shown to extend their lives.

Nexavar (also called sorafenib) is not a cure but has the potential to help people live longer, typically by six months.

Bayer, which offered a patient access scheme where the company would provide every fourth packet for free, said it will appeal the decision.

The drug is suitable for advanced hepatocellular carcinoma (HCC), which occurs when the cancer tumour originates in the liver rather than spreading there from elsewhere in the body.

The only hope of a cure is surgery but very few patients are eligible for this.

More than 3,000 people in the UK are diagnosed with liver cancer every year and more than 3,200 die from the disease.

In 2006, 3,190 people were diagnosed with liver cancer in the UK.

In 2007, 3,202 died of the disease, according to the most recent figures available from Cancer Research UK.

Only around 20 per cent of patients are alive one year after diagnosis, dropping to 5 per cent after five years.

Andrew Dillon, chief executive of Nice, said: "We were disappointed not to have been able to recommend the use of sorafenib but after carefully considering all the evidence, including the proposed patient access scheme in which the manufacturer offered to provide every fourth pack free, sorafenib does not provide enough benefit to patients to justify its high cost.

"We have recently changed our approach to appraising high cost treatments which can extend life for terminally ill patients.

"This has meant that more of them are now being recommended. We looked at sorafenib in just the same way but the price being asked by Bayer is simply too high to justify using NHS money which could be spent on better value cancer treatments."

Mike Hobday, head of campaigns at Macmillan Cancer Support, said: "We are extremely disappointed that Nice has decided not to recommend sorafenib as a treatment for people with advanced liver cancer.

"It is a scandal that the only licensed drug proven to significantly prolong the lives of people with this devastating disease has been rejected, leaving them with no treatment options.

"It's time to rethink the way new cancer drugs are assessed to ensure fairer access to drugs for people with rarer cancers."

Bayer said Nice did not appear to have acted in accordance with its own processes.

Nicole Farmer, business unit head of Bayer Schering Pharma oncology in the UK, said: "While we recognise that Nice has difficult decisions to make, we are without doubt that today's guidance goes completely against UK HCC treatment guidelines, Nice's own 'end of life' criteria and the current government strategy to bring cancer outcomes in line with Europe.

"Bayer has proposed an excellent patient access scheme for Nexavar, unique to the UK, to enable patients in this country to benefit from this life-extending medicine.

"We believed we had satisfied Nice's criteria for how Nexavar would be assessed - however, the 'goal posts' appeared to have moved.

"We shall appeal against the decision and, if we are successful, this will enable the NHS to offer a similar level of access to Nexavar as other EU countries such as France, Germany, Spain, Italy and Romania where it has already been granted funding."

Kate Spall fought for the drug for her mother Pamela Northcott, who died in 2007.

Her local health trust in Wales denied the drug but Mrs Spall won two months of treatment for her mother.

Mrs Spall said Nice's end of life policy and recommendations contained in a 2007 review by cancer tsar Professor Mike Richards had been ignored.

"Yet again we are subjected to more spin and no substance," she said.

"When are the government going to wake up and realise we want clinicians to decide on our treatments - not accountants and statisticians?

"Today, I put my heart and soul into ensuring that no cancer patient ever goes through the hell that she suffered and I have won cases for over 250 UK patients, with two new patients' requests each day.

"So despite this devastating news, in my mother's name I will continue to fight for UK cancer patients and win so they don't have to spend the last few months of their lives fighting for themselves, often by themselves".

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "The results of a large international trial found that sorafenib (Nexavar) helps patients with liver cancer to live longer.

"This drug has an effect in people with advanced liver cancer who are unable to have surgery or any other treatments, so we are disappointed that the manufacturers have been unable to reach an agreement to enable Nice to recommend this drug.

"It is particularly frustrating that cancer patients in the UK are unable to access this drug when it is routinely available elsewhere in the world."

ebooks
ebookA delicious collection of 50 meaty main courses
Life and Style
ebookNow available in paperback
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    SThree: Trainee Recruitment Consultant - Dublin

    £13676.46 - £16411.61 per annum + OTE: SThree: SThree Trainee Recruitment Cons...

    Ashdown Group: Marketing or Business Graduate Opportunity - Norwich - £22,000

    £18000 - £22000 per annum + training: Ashdown Group: Business and Marketing Gr...

    SThree: Trainee Recruitment Consultant

    £20000 - £25000 per annum + Commission: SThree: Are you great at building rela...

    Ashdown Group: Database Analyst - Birmingham - £22,000 plus benefits

    £20000 - £22000 per annum + excellent benefits: Ashdown Group: Application Sup...

    Day In a Page

    Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

    Fishing is on Nigel Farage's mind

    Ukip leader casts a line to the disaffected
    Who is bombing whom in the Middle East? It's amazing they don't all hit each other

    Who is bombing whom in the Middle East?

    Robert Fisk untangles the countries and factions
    China's influence on fashion: At the top of the game both creatively and commercially

    China's influence on fashion

    At the top of the game both creatively and commercially
    Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

    The man known as GOD has a reputation for getting the job done

    Lord O'Donnell's three principles of rule
    Rainbow shades: It's all bright on the night

    Rainbow shades

    It's all bright on the night
    'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

    Bread from heaven

    Dutch survivors thank RAF for World War II drop that saved millions
    Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

    How 'the Axe' helped Labour

    UK will be 'run for the wealthy and powerful' if Tories retain power
    Rare and exclusive video shows the horrific price paid by activists for challenging the rule of jihadist extremists in Syria

    The price to be paid for challenging the rule of extremists

    A revolution now 'consuming its own children'
    Welcome to the world of Megagames

    Welcome to the world of Megagames

    300 players take part in Watch the Skies! board game in London
    'Nymphomaniac' actress reveals what it was really like to star in one of the most explicit films ever

    Charlotte Gainsbourg on 'Nymphomaniac'

    Starring in one of the most explicit films ever
    Robert Fisk in Abu Dhabi: The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers

    Robert Fisk in Abu Dhabi

    The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers
    Vince Cable interview: Charging fees for employment tribunals was 'a very bad move'

    Vince Cable exclusive interview

    Charging fees for employment tribunals was 'a very bad move'
    Iwan Rheon interview: Game of Thrones star returns to his Welsh roots to record debut album

    Iwan Rheon is returning to his Welsh roots

    Rheon is best known for his role as the Bastard of Bolton. It's gruelling playing a sadistic torturer, he tells Craig McLean, but it hasn't stopped him recording an album of Welsh psychedelia
    Morne Hardenberg interview: Cameraman for BBC's upcoming show Shark on filming the ocean's most dangerous predator

    It's time for my close-up

    Meet the man who films great whites for a living
    Increasing numbers of homeless people in America keep their mobile phones on the streets

    Homeless people keep mobile phones

    A homeless person with a smartphone is a common sight in the US. And that's creating a network where the 'hobo' community can share information - and fight stigma - like never before